Rheumatology International

, Volume 32, Issue 1, pp 145–150

Theory-based analysis of anti-inflammatory effect of infliximab on Crohn’s disease and rheumatoid arthritis

  • Koji Kimura
  • Risa Takayanagi
  • Haruko Yokoyama
  • Yasuhiko Yamada
Original Article

DOI: 10.1007/s00296-010-1553-8

Cite this article as:
Kimura, K., Takayanagi, R., Yokoyama, H. et al. Rheumatol Int (2012) 32: 145. doi:10.1007/s00296-010-1553-8

Abstract

In Japan, the recommended dosage regimens of infliximab (IFX) for treatment of rheumatoid arthritis (RA) and Crohn’s disease (CD) are different. However, the differences have not been analyzed theoretically. In a previous study, we constructed a pharmacokinetic–pharmacodynamic model to investigate the effects of IFX for CD and found it useful to establish a rational dosage regimen of IFX for individual patients with CD. In the present study, we investigated whether the theory-based model could be used for cases of RA and also used it to evaluate the validity of the dosage regimen. The results obtained with our model were in good agreement with observed tender joint count (TJC) ratio data, which was considered to show the validity of our analysis. Thus, we concluded that the model could be used for patients with RA. Furthermore, a second administration of IFX given 2 weeks after the first infusion was important to achieve remission in the early stage of RA. We also compared the estimated pharmacodynamic parameters of RA with those of CD. The elimination rate constant of inflammation in RA was greater than that in CD, suggesting that the recovery from inflammation in RA is faster than that in CD, and indicating a reason for the difference in dosage between RA and CD. In conclusion, use of our model in light of the individual quantitative factor of tumor necrosis factor (TNF)-α allows establishment of IFX dosage regimens for individual patients.

Keywords

Infliximab Crohn’s disease Rheumatoid arthritis Pharmacokinetics 

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Koji Kimura
    • 1
  • Risa Takayanagi
    • 1
  • Haruko Yokoyama
    • 1
  • Yasuhiko Yamada
    • 1
  1. 1.Department of Clinical Evaluation of Drug Efficacy, School of PharmacyTokyo University of Pharmacy and Life SciencesHachiojiJapan